Shanghai ZJ Bio-Tech Co's Total Assets for the quarter that ended in Mar. 2026 was ¥3,706.7 Mil.
During the past 12 months, Shanghai ZJ Bio-Tech Co's average Total Assets Growth Rate was -10.30% per year.
During the past 3 years, the average Total Assets Growth Rate was -18.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 0.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 17.30% per year.
During the past 13 years, Shanghai ZJ Bio-Tech Co's highest 3-Year average Total Assets Growth Rate was 61.40%. The lowest was -18.50%. And the median was 23.75%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Shanghai ZJ Bio-Tech Co's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Shanghai ZJ Bio-Tech Co Total Assets Related Terms
Shanghai ZJ Bio-Tech Co Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Shanghai ZJ Bio-Tech Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a Total Assets of ¥3,706.7 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Shanghai ZJ Bio-Tech Co and its competitors.
Is Shanghai ZJ Bio-Tech Co's Total Assets too high?
Shanghai ZJ Bio-Tech Co's current Total Assets is ¥3,706.7 Mil. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's Total Assets compare to ABT and SYK?
Shanghai ZJ Bio-Tech Co's Total Assets of ¥3,706.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. Shanghai ZJ Bio-Tech Co's current Total Assets is ¥3,706.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.93, compared to a current price of ¥15.09 — trading 52% above its estimated fair value. The current Total Assets is ¥3,706.7 Mil. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current Total Assets is ¥3,706.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.09 is trading 52% above its estimated GF Value™ of ¥9.93.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
Total Assets: ¥3,706.7 Mil
GF Value™: ¥9.93 vs. price of ¥15.09 (52% above fair value)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
69GF Score
Get the complete analysis for SHSE:688317
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
